脊索瘤组织中Brachyury 表达与预后的关系

摘要

目的:探讨脊索瘤组织中Brachyury的表达及意义.方法:征集78例脊索瘤组织、7例脊索瘤癌旁正常组织和6例胚胎脊索组织用于制作组织芯片,采用免疫组化法检测Brahcyury的表达.采用回顾性分析,临床追踪57例患者,其中无病存活患者27例,带瘤存活患者7例,因脊索瘤死亡患者23例.结果:Brachyury在脊索瘤组织中的阳性表达率为75.64%(59/78),与癌旁正常组织中的4/7比较差异无统计学意义(H=22.669,P=0.263),其在骶骨发病者的阳性表达水平高于发病于活动脊柱者(H=2.292,P=0.022).不同Brachyury表达水平的患者Kaplan-Meier生存曲线差异无统计学意义(χ2=0.432,P=0.933).不同疾病状态患者脊索瘤组织中Brachyury的表达水平差异亦无统计学意义(H=2.605,P=0.272).结论:Brachyury并不能作为预测脊索瘤预后的特异性分子标志物.%Aim:To research the association of expression of Brachyury with the prognosis of chordoma. Methods:A total of 78 cases of chordoma tissues, 7 cases of notochord controls near chordoma tissue and 6 cases of embryonic noto-chord tissue were collected to construct tissue microarray, and immunohistochemistry was used to detect the expression of Brachyury. A total of 57 chordoma patients were followed up, 27 patients were alive without evidence of disease, 7 patients were alive with disease, and 23 patients died of chordoma. Results:Brachyury expression were positive in 75. 64% ( 59/ 78 ) chordoma tissue, 4/7 notochord normal controls and 6/6 embryonic notochord tissue. Brachyury positive expression level in chordoma tissue did not differ from that of notochord normal tissue( H = 22. 669 ,P =0. 263 ). Brachyury positive expression rate in mobile spine was lower than that in sacrum group( H = 2. 292 ,P = 0.022 ). There were no significant differences among patients with different disease status in Brachyury expression( H = 2. 605 ,P = 0. 272 ), and the survival curves of patients with different Brachyury expression level had no difference(X2= 0. 432, P =0. 933 ). Conclusion:Brachyury can not be used as specific biomarker to predict the prognosis of chordoma.